Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension.

@article{Hiramoto2007EffectOB,
  title={Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension.},
  author={Yoshimune Hiramoto and Wataru Shioyama and Tadashi Kuroda and Mitsuru Masaki and Shoko Sugiyama and Kitaro Okamoto and Hisao Hirota and Yasushi Fujio and Masatsugu Hori and Keiko Yamauchi-Takihara},
  journal={Circulation journal : official journal of the Japanese Circulation Society},
  year={2007},
  volume={71 3},
  pages={367-9}
}
BACKGROUND Pulmonary arterial hypertension (PAH) is a progressive disease with high mortality. An orally active dual endothelin (ET) receptor antagonist, bosentan, has been reported to improve exercise capacity and survival in patients with PAH. Plasma ET-1 concentration is known to be increased in PAH patients; however, the effect of bosentan on ET-1 concentration has not yet been investigated. METHODS AND RESULTS The concentration of ET-1 after bosentan administration was examined in 7 PAH… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Similar Papers

Loading similar papers…